TMTamra McKenzie‐Johnson

Tamra McKenzie‐Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tamra McKenzie‐Johnson has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Access to Cancer Care

    by Jennifer J. Butler, Anita T. Johnson, Tamra S. A. McKenzie-Johnson

    Access to cancer care is crucial for patients to receive equitable treatment and enhance survival rates. While it is well-established that regular screenings can reduce morbidity and mortality, not all patients have the same access to these services. Barriers to screening include racial and socioeconomic disparities, geographic limitations, lack of insurance, and insufficient educational awareness. To improve access to cancer care, interventions such as enhancing health insurance coverage, bridging the urban-rural divide in cancer care through telemedicine and mobile clinics, and establishing community-based initiatives with community health workers are essential. Additionally, developing innovative methods to enhance screening, including self-sampling options, will be vital in improving cancer survival rates.


  • Addressing Breast Cancer Disparities: A Comprehensive Approach to Health Equity

    by Eliel N. Arrey, Darren GoPaul, David Anderson, Joel Okoli, Tamra McKenzie‐Johnson

    This article addresses the persistent disparities in breast cancer outcomes across different racial, ethnic, and socioeconomic groups despite advancements in diagnosis and treatment. The disparities are rooted in various factors, including access to care, socioeconomic status, and cultural barriers. The article emphasizes the need for targeted interventions, such as expanding insurance coverage, mobile mammography units, and culturally tailored outreach programs to promote health equity. Achieving this requires comprehensive strategies addressing systemic and social determinants of health.


  • Barriers to Cancer Care in the LGBTQ+ Community

    by Shebiki Beaton, Tamra McKenzie‐Johnson

    Individuals that identify as lesbian, gay, bisexual, transgender, queer, intersex, and asexual (LGBTQIA) make up a medically underserved population, that experience disparities in cancer care. Specific cancer incidence and mortality in this population is understudied, as national cancer registries and cancer surveys have limited data about sexual orientation or gender identity. The LGBTQIA community face disparate cancer outcomes in prevention, screening, diagnosis, and treatment due to barriers that limit access to cancer care. To better understand these concerns, we will take a deep dive into the three primary barriers that prevent access to cancer care: personal, provider and systems barriers.


  • Open Access

    Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

    by Gee Young Lee, Mohamed Mubasher, Tamra S. McKenzie, Nicole C. Schmitt, Merry E. Sebelik, Carrie E. Flanagan, Badi El Osta, Maya B. Cothran, Hadiyah-Nicole Green

    Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.